Pilot Study of MEND Protocol for Alzheimer’s Shows Results in Those with Mild Decline

Pilot Study of MEND Protocol for Alzheimer’s Shows Results in Those with Mild Decline
At the recent Alzheimer’s Association International Conference (AAIC) 2016, held in Toronto, Canada, Muses Labs presented data from a pilot study of its MEND Protocol for treatment of early Alzheimer’s disease. The few drugs available today to slow the progression of Alzheimer’s disease target individual brain factors. Plenty of research, however, shows that dementia is linked to an array of risk factors, suggesting that some form of a combination therapy is likely to be more effective. But the factors involved also vary among individuals, and a one-combination-therapy-that-fits-all approach is unsuitable.  Muses Labs reports that it has found
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *